Emory Healthcare Achieves Groundbreaking Robotic Endovascular Procedures with Microbot Medical’s LIBERTY® System

Key Highlights for Investors

• World’s First Robotic Prostatic Artery Embolization (PAE) and Y-90 Mapping:
  Emory Healthcare has successfully completed the world’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH), and the first robotic Y-90 radioembolization mapping for liver cancer, using Microbot Medical’s LIBERTY® Endovascular Robotic System.
• FDA-Cleared, Single-Use, Remotely Operated Robotic System:
  LIBERTY® is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, highlighting its regulatory and technological leadership.
• Potential to Set New Standards of Care:
  The successful completion of these procedures highlights the system’s potential to become the standard for endovascular robotic navigation, potentially mirroring the rise of robotic-assisted prostatectomy in prostate cancer treatment.
• Commercialization Milestones:
  Microbot Medical commenced Limited Market Release of LIBERTY® in November 2025 and is targeting Full Market Release at the Society of Interventional Radiology conference in April 2026.
• Large Addressable Markets:
  BPH affects approximately 40 million men in the U.S. alone, and liver cancer remains a significant area of unmet need, highlighting significant market potential for the LIBERTY® system.

Detailed Report

Atlanta, GA and Hingham, MA, March 26, 2026 – Emory Healthcare has made medical history by successfully completing the world’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH), using Microbot Medical’s (NASDAQ: MBOT) LIBERTY® Endovascular Robotic System. In addition, Emory specialists have completed the first robotic Yttrium-90 (Y-90) radioembolization mapping for liver cancer using the same system. These milestone procedures underscore the rapid adoption of robotic technology across multiple endovascular case types and signal a potential paradigm shift in vascular and cancer therapies.

Clinical Significance and Innovation

The LIBERTY® System enables minimally invasive, image-guided procedures with high precision, which can be crucial in treating complex vascular conditions. The first robotic PAE, performed by Dr. Zachary L. Bercu and his team at Emory, provides an alternative to surgery for BPH, a condition affecting around 40 million men in the U.S. The system’s advanced navigation aids in overcoming challenging anatomy, and its fine motor control allows for efficient access to target sites inside blood vessels.

For liver cancer, the LIBERTY® system was used for precision mapping prior to Y-90 therapy, which involves injecting radioactive beads into vessels supplying the tumor. This targeted approach delivers high-dose radiation directly to cancer cells while sparing healthy tissue, supporting the trend toward more personalized, less invasive cancer therapies.

Potential Impact on Healthcare and Market Adoption

Microbot Medical’s management believes LIBERTY® could revolutionize endovascular care, setting a new standard for PAE as robotic-assisted prostatectomy did for prostate cancer. The successful procedures at Emory reinforce confidence in the system’s innovation and the benefits it offers to clinicians, patients, and hospital workflow. The flexibility and precision of the LIBERTY® system could accelerate its adoption across a broad spectrum of vascular and interventional oncology procedures.

Commercialization Strategy and Market Opportunity

Microbot Medical commenced the Limited Market Release of LIBERTY® in November 2025 and will showcase the system for Full Market Release during the April 2026 Society of Interventional Radiology conference. This strategic rollout could catalyze market adoption and revenue growth, positioning the company at the forefront of robotic endovascular treatment.

With an addressable market that includes tens of millions of BPH patients and a significant liver cancer population, the system’s unique FDA clearance and single-use design position Microbot Medical for substantial commercial opportunity.

Company and Hospital Profile

Emory Healthcare is Georgia’s largest academic health system, operating 11 hospitals and employing 29,500 staff. Its reach extends throughout Georgia, including partnerships with regional affiliates and a clinically integrated physician network.

Microbot Medical is a commercial-stage medical device company focused on robotic technology for vascular procedures. The company’s strong intellectual property portfolio and commitment to innovation underpin its leadership in this emerging sector.

Key Takeaways for Shareholders

• The world’s first robotic PAE and Y-90 mapping procedures validate the clinical utility and technological advancement of LIBERTY®, potentially increasing the system’s desirability and adoption.
• These achievements could be significant catalysts for Microbot Medical’s share price, especially as the company approaches full market release and broader commercial adoption.
• Investors should monitor further clinical results, regulatory updates, and commercialization milestones, as these could materially affect the company’s valuation and growth trajectory.
• The company faces risks related to market acceptance, regulatory pathways, geopolitical factors, and intellectual property, as outlined in their public filings.

Contacts for Further Information

Investor Relations: [email protected]
Media: [email protected]
Emory Healthcare Media Contact: Janet Christenbury – [email protected]

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties, including but not limited to market conditions, regulatory developments, commercialization risks, and geopolitical events. Investors are urged to conduct their own due diligence and review the company’s filings with the U.S. Securities and Exchange Commission.

View Microbot Medical Inc. Historical chart here